Slingshot members are tracking this event:

Lannett Receives FDA Approval For Temozolomide Capsules

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
LCI Community voting in process

Additional Information

Management Comment "Temozolomide is an important chemotherapy agent used to treat a certain type of brain tumor," said Arthur Bedrosian, chief executive officer of Lannett. "This product represents the first approval received from our recently completed acquisition of KU. We expect to commence marketing shortly."
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 11, 2016
Related Keywords Temozolomide, Temodar